Immunitybio Inc
$ 6.92
-5.08%
05 Jun - close price
- Market Cap 7,247,690,000 USD
- Current Price $ 6.92
- High / Low $ 7.29 / 6.79
- Stock P/E N/A
- Book Value -0.83
- EPS -0.85
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE N/A %
- 52 Week High 12.43
- 52 Week Low 1.95
About
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Analyst Target Price
$13.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-23 | 2025-11-04 | 2025-08-05 | 2025-05-12 | 2025-03-03 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-19 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.08 | -0.06 | -0.07 | -0.1 | -0.15 | -0.08 | -0.12 | -0.2 | -0.2 | -0.38 | -0.19 | -0.32 |
| Estimated EPS | -0.07 | -0.1106 | -0.1 | -0.1 | -0.16 | -0.13 | -0.18 | -0.15 | -0.16 | -0.18 | -0.18 | -0.23 |
| Surprise | -0.01 | 0.0506 | 0.03 | 0 | 0.01 | 0.05 | 0.06 | -0.05 | -0.04 | -0.2 | -0.01 | -0.09 |
| Surprise Percentage | -14.2857% | 45.7505% | 30% | 0% | 6.25% | 38.4615% | 33.3333% | -33.3333% | -25% | -111.1111% | -5.5556% | -39.1304% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IBRX
2026-06-06 03:09:20
ImmunityBio Inc Director Barry Simon sold 23,033 shares of the company on June 4, 2026, reducing his total holdings to 2,827,788 shares. This sale is part of a pattern over the past year where Simon has sold 425,000 shares with no insider purchases. ImmunityBio, a clinical-stage biotechnology company, is currently trading at $7.18, significantly below its GF Value of $41.98, leading GuruFocus to classify it as a "Possible Value Trap, Think Twice."
2026-06-05 21:40:08
ImmunityBio director Barry J. Simon sold 23,033 shares of Common Stock at a weighted average price of $7.1769 per share on June 4, 2026. This open-market sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. Following the transaction, Simon directly holds 2,827,788 shares, indicating this was a routine portfolio management activity.
2026-06-05 09:39:29
ImmunityBio (IBRX) saw its stock drop 5.6% following the release of new Phase 3 data for its ANKTIVA drug in advanced non-small cell lung cancer at the 2026 ASCO Annual Meeting. This data, alongside continued development in bladder cancer, is crucial for ImmunityBio's investment narrative, as the company needs to expand ANKTIVA's application beyond its initial approval to achieve significant revenue growth and profitability. The article highlights that analysts project substantial revenue and earnings growth for ImmunityBio by 2029, with a fair value indicating a significant upside, provided the company can successfully diversify its product offerings and manage its financial constraints.
2026-06-04 16:38:44
The article highlights ImmunityBio, Inc.'s ANKTIVA, discussing its strong clinical and commercial progress. ANKTIVA has shown efficacy and durability in treating bladder and lung cancer, leading to expanding global approvals. The company also maintains solid financials and is developing new BCG strains to address shortages.
2026-06-04 14:38:44
This article details an SEC Form 144 filing by ImmunityBio, Inc. (IBRX) on June 4, 2026, primarily concerning the proposed sale of securities. The filing indicates a significant number of shares (268,033) with an aggregate market value of over $2.9 million intended for sale, acquired through "various methods & dates" from the issuer since 2013. The company also recently announced positive clinical trial data and FDA acceptance for one of its therapies.
2026-06-03 14:13:25
ImmunityBio shares rose 3% after the company submitted a comprehensive response to the FDA regarding promotional compliance issues, specifically concerning a television advertisement and a podcast. The biotech firm confirmed the ad was never broadcast and removed the podcast, also implementing enhanced advertising compliance measures and executive training. The company emphasized its commitment to distinguishing between investigational pipeline aspirations and approved therapy indications.
